Both the mTOR- and TF-targeted therapy induced a multifaceted remodeling of tumor microenvironment, reflecting not only a diminished hypercoagulable state (fibrin level), but also a reduced stromal fibrosis (collagen distribution), compromised vessel density and/or maturity (CD31 and/or α-SMA) as well as a substantially decreased infiltration of M2-type TAMs (CD206/F4/80). This evidence concerns the gene MRC1 and neoplasm.